Recent Progress in Mass Spectrometry-based Metabolomics for Colorectal Cancer  

作　　者：XIAO Chulei CHI Quan WANG Xian 

机构地区：[1]Key Laboratory of Analytical Chemistry of the State Ethnic Affairs Commission,School of Chemistry and Materials Science,South-Central Minzu University,Wuhan,430074,P.R.China

出　　处：《Chemical Research in Chinese Universities》2022年第4期886-893,共8页高等学校化学研究（英文版）

基　　金：supported by the National Natural Science Foundation of China(No.21675176);the Key Research and Development Program of Hubei Province,China(No.2020BCB032);the Fundamental Research Funds for the Central Universities,South-Central Minzu University,China(No.CZP21002).

摘　　要：Metabolomics,one of the latest omics technologies,is employed to reveal overall metabolic trajectories,identify disease causative mechanisms and provide information for preventive diagnosis and drug targeting.Cancer is a disease known to alter cellular metabolism and so metabolomics can play an important role in the early diagnosis of cancer and in the evaluation of medical interventions and treatments for cancer.Many metabolomics studies rely on high-sensitive and high-throughput mass spectrometry platforms.In recent years,various mass spectrometry(MS)methodologies have been developed and enriched the scope of metabolite detection,contributing to disease studies,such as diabetes,cancer,and depression.Colorectal cancer is the third most diagnosed cancer worldwide and its incidence ranked third in China.This review focuses on the mass spectrometry technologies in metabolomics and summarizes the progress of metabolomics research in colorectal cancer.

关 键 词：Metabolomics Mass spectrometry Colorectal cancer BIOMARKER 

分 类 号：R735.3[医药卫生—肿瘤]